Literature DB >> 12054626

Protein engineering and properties of human metalloproteinase and thrombospondin 1.

Ping Wei1, Yun-Ge Zhao, Li Zhuang, Douglas R Hurst, Steve Ruben, Qing-Xiang Amy Sang.   

Abstract

This work generated many truncated proteins and Glu(385) to Ala (E(385)/A) mutants of the human metalloproteinase and thrombospondin 1 (METH-1 or ADAMTS1) and specific antibodies. METH-1 was an active endopeptidase and both the metalloproteinase and the disintegrin/cysteine-rich domains were required for the proteinase activity. A point mutation at the zinc-binding site (E(385)/A) abolished the catalytic activity. METH-1 protein function may be modulated through proteolytic cleavage at multiple sites. One 135 kDa species had an NH(2)-terminal sequence of L(33)GRPSEEDEE. A species at 115 kDa and some other protein bands began with F(236)VSSHRYV(243), indicating that METH-1 proenzyme might be activated by a proprotein convertase such as furin by cleaving the R(235)-F(236) peptide bond. This cleavage was not an autocatalytic process since the E(385)/A mutants were also processed. Furthermore, a 52 kDa band with an NH(2)-terminal sequence of L(800)KEPLTIQV resulted from the digestion between the first and the second thrombospondin 1-like motifs in the spacer region of the extracellular matrix-binding domains.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12054626     DOI: 10.1016/S0006-291X(02)00255-3

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Purification of an insect derived recombinant human ADAMTS-1 reveals novel gelatin (type I collagen) degrading activities.

Authors:  Thomas Lind; Mark A Birch; Norman McKie
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

2.  Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer's disease.

Authors:  Donna M Wilcock
Journal:  Curr Gerontol Geriatr Res       Date:  2012-02-21

3.  Exosite inhibition of ADAMTS-5 by a glycoconjugated arylsulfonamide.

Authors:  Salvatore Santamaria; Doretta Cuffaro; Elisa Nuti; Lidia Ciccone; Tiziano Tuccinardi; Francesca Liva; Felicia D'Andrea; Rens de Groot; Armando Rossello; Josefin Ahnström
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

Review 4.  Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis.

Authors:  Donna M Wilcock; W Sue T Griffin
Journal:  J Neuroinflammation       Date:  2013-07-16       Impact factor: 8.322

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.